Prnewswire·2026-02-02 14:00Core Viewpoint - Anixa Biosciences has received approval for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant step towards its commercialization [1][2]. Group 1: Company Developments - The USAN Council approved the non-proprietary name for Anixa's CAR-T therapy, which follows prior approval from the WHO's INN Expert Committee, allowing for a globally recognized drug name [1][2]. - The company is focused on executing its ongoing Phase 1 trial of liraltagene autoleucel, in partnership with Moffitt Cancer Center, aimed at treating ovarian cancer [2][3]. - Liraltagene autoleucel is a novel CAR-T therapy that targets the follicle stimulating hormone receptor (FSHR), which is expressed on normal ovarian cells and certain cancer cells [3]. Group 2: Technology and Research - The CAR-T technology, known as chimeric endocrine receptor-T cell (CER-T) therapy, utilizes a natural ligand to bind to the FSHR receptor on tumor cells, differentiating it from traditional cell therapies [3]. - The ongoing Phase 1 trial is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3]. Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at treating and preventing breast and ovarian cancer, developed in collaboration with Cleveland Clinic, which is entitled to royalties from these technologies [4]. - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [4].